{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:12:47Z","timestamp":1790712767897,"version":"4.1.0"},"reference-count":211,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.jaad.2013.08.033","type":"journal-article","created":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T09:13:20Z","timestamp":1389777200000},"page":"223.e1-223.e17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":271,"title":["Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome)"],"prefix":"10.1016","volume":"70","author":[{"given":"Sarah I.","family":"Jawed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Myskowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Querfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2013.08.033_bib1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaad.2010.08.037","article-title":"S\u00e9zary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)","volume":"64","author":"Olsen","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib2","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","article-title":"Review of the treatment of mycosis fungoides and S\u00e9zary syndrome: a stage-based approach","volume":"6","author":"Horwitz","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jaad.2013.08.033_bib4","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/archderm.1979.04010090053026","article-title":"Cutaneous T-cell lymphomas. Summary of the Mycosis Fungoides Cooperative Group-National Cancer Institute Workshop","volume":"115","author":"Lamberg","year":"1979","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.08.033_bib6","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2013.08.033_bib7","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and S\u00e9zary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib8","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/archderm.1996.03890350051009","article-title":"Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis","volume":"132","author":"Kim","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib9","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib10","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0190-9622(99)70079-4","article-title":"Prognostic factor analysis in mycosis fungoides\/S\u00e9zary syndrome","volume":"40","author":"Diamandidou","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib11","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V92.4.1150","article-title":"Transformation of mycosis fungoides\/S\u00e9zary syndrome: clinical characteristics and prognosis","volume":"92","author":"Diamandidou","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.08.033_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1523-1747.2000.00830.x","article-title":"Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides","volume":"114","author":"Fraser-Andrews","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1749-6632.2002.tb04208.x","article-title":"Regulation of leukocyte-endothelial interactions by glucocorticoids","volume":"966","author":"Pitzalis","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaad.2013.08.033_bib14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000236781","article-title":"Glucocorticoid-induced apoptosis of lymphoid cells","volume":"105","author":"Schwartzman","year":"1994","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaad.2013.08.033_bib15","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1056\/NEJM199704103361506","article-title":"Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases","volume":"336","author":"Barnes","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2013.08.033_bib16","first-page":"655","article-title":"Skin directed therapy for mycosis fungoides: a review","volume":"7","author":"Berthelot","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archderm.1968.01610080069013","article-title":"Treatment of mycosis fungoides with various strengths of fluocinolone acetonide cream","volume":"97","author":"Farber","year":"1968","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/1097-0142(196602)19:2<237::AID-CNCR2820190216>3.0.CO;2-P","article-title":"Therapy of mycosis fungoides with topically applied fluocinolone acetonide under occlusive dressing","volume":"19","author":"Farber","year":"1966","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2013.08.033_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-4362.2003.01644.x","article-title":"Treatment of mycosis fungoides\/S\u00e9zary syndrome: the University of California, San Francisco (UCSF) approach","volume":"42","author":"Zackheim","year":"2003","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000255191","article-title":"Observations upon the use of topical triamcinolone acetonide preparations in various concentrations","volume":"122","author":"Cohen","year":"1961","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaad.2013.08.033_bib21","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archderm.139.2.165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib23","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.1987.5.11.1796","article-title":"Mycosis fungoides: management with topical nitrogen mustard","volume":"5","author":"Hoppe","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib24","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/archderm.1982.01650160024015","article-title":"The treatment of mycosis fungoides with ointment-based mechlorethamine","volume":"118","author":"Price","year":"1982","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib25","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0190-9622(88)70223-6","article-title":"Topical mechlorethamine therapy for early stage mycosis fungoides","volume":"19","author":"Ramsay","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib26","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","article-title":"Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma","volume":"20","author":"Vonderheid","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib27","first-page":"681","article-title":"A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy","volume":"63","author":"Vonderheid","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.jaad.2013.08.033_bib28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2340\/00015555655358","article-title":"Topical nitrogen mustard in early mycosis fungoides. A 12-year experience","volume":"65","author":"Zachariae","year":"1985","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2013.08.033_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1468-3083.2011.04433.x","article-title":"Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis","volume":"27","author":"Lindahl","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.08.033_bib31","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/archderm.141.9.1117","article-title":"Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study","volume":"141","author":"de Quatrebarbes","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib32","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1517\/14656566.7.7.907","article-title":"Bexarotene in the treatment of cutaneous T-cell lymphoma","volume":"7","author":"Querfeld","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jaad.2013.08.033_bib33","first-page":"1234","article-title":"Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"8","author":"Zhang","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2013.08.033_bib34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib35","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2003.09.005","article-title":"Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study","volume":"50","author":"Apisarnthanarax","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib36","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1365-2230.1986.tb00509.x","article-title":"Distribution of T cell subsets and Langerhans cells in mycosis fungoides, and the effect of PUVA therapy","volume":"11","author":"Cox","year":"1986","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1749-6632.2001.tb03722.x","article-title":"Photoactivational cytokine-modulatory action of 8-methoxypsoralen plus ultraviolet A in lymphocytes, monocytes, and cutaneous T cell lymphoma cells","volume":"941","author":"Tokura","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaad.2013.08.033_bib38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/1523-1747.ep12329711","article-title":"Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action","volume":"107","author":"Yoo","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib39","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1468-3083.2003.00614_10.x","article-title":"The influence of psoralen + ultraviolet A treatment on the duration of remission and prognosis in mycosis fungoides","volume":"17","author":"Oguz","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.08.033_bib40","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2340\/0001555576475478","article-title":"PUVA in early mycosis fungoides may give long-term remission and delay extracutaneous spread","volume":"76","author":"Roupe","year":"1996","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2013.08.033_bib41","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0190-9622(95)90241-4","article-title":"Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up","volume":"33","author":"Herrmann","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib42","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0190-9622(84)70030-2","article-title":"Photochemotherapy for cutaneous T cell lymphoma. A follow-up study","volume":"10","author":"Honigsmann","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2340\/00015555614751","article-title":"Photochemotherapy (PUVA) in the pretumour stage of mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Study Group","volume":"61","author":"Molin","year":"1981","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2013.08.033_bib44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(80)92937-2","article-title":"Photochemotherapy in mycosis fungoides. A study of 73 patients","volume":"2","author":"Briffa","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2013.08.033_bib45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/archderm.1979.04010010022007","article-title":"Photochemotherapy for mycosis fungoides: a clinical and histological study","volume":"115","author":"Lowe","year":"1979","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib46","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archderm.141.3.305","article-title":"Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy","volume":"141","author":"Querfeld","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib47","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/cncr.10706","article-title":"Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma","volume":"95","author":"Chiarion-Sileni","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2013.08.033_bib48","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1995.13.1.257","article-title":"Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the S\u00e9zary syndrome","volume":"13","author":"Kuzel","year":"1995","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.jaad.2013.08.033_bib49","doi-asserted-by":"crossref","first-page":"198S","DOI":"10.1111\/1523-1747.ep12875523","article-title":"Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma","volume":"95","author":"Roenigk","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib50","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1046\/j.1365-2133.1999.02898.x","article-title":"The effects of ultraviolet radiation on the human immune system","volume":"140","author":"Duthie","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib51","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1067\/mjd.2003.80","article-title":"Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study","volume":"48","author":"Diederen","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1600-0781.1995.tb00160.x","article-title":"Immunomodulation at the initiation of phototherapy and photochemotherapy","volume":"11","author":"Guckian","year":"1995","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2013.08.033_bib53","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaad.2005.03.012","article-title":"Narrowband ultraviolet B phototherapy to clear and maintain clearance in patients with mycosis fungoides","volume":"53","author":"Boztepe","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib54","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0781.2007.00314.x","article-title":"Narrow-band ultraviolet therapy in early-stage mycosis fungoides: study on 20 patients","volume":"23","author":"Brazzelli","year":"2007","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2013.08.033_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000161114","article-title":"Treatment of early stages of mycosis fungoides with narrowband ultraviolet B. A clinical, histological and molecular evaluation of results","volume":"218","author":"Dereure","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2013.08.033_bib56","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1067\/mjd.2002.120911","article-title":"Narrowband UVB phototherapy for early-stage mycosis fungoides","volume":"47","author":"Gathers","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib57","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2230.2005.01840.x","article-title":"Narrow-band UVB in the treatment of early stage mycosis fungoides: report of 16 patients","volume":"30","author":"Ghodsi","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib58","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1468-3083.2006.01635.x","article-title":"Narrowband UVB phototherapy for early-stage mycosis fungoides: evaluation of clinical and histopathological changes","volume":"20","author":"Gokdemir","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.08.033_bib59","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archderm.135.11.1377","article-title":"Narrowband (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides","volume":"135","author":"Hofer","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib60","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1468-3083.2005.01317.x","article-title":"Efficacy of narrowband UVB phototherapy in early stage of mycosis fungoides","volume":"20","author":"Kural","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.08.033_bib61","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1468-3083.2006.01557.x","article-title":"UVB in the management of early stage mycosis fungoides","volume":"20","author":"Pavlotsky","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.08.033_bib62","first-page":"660","article-title":"Narrow-band ultraviolet B phototherapy for early stage mycosis fungoides","volume":"18","author":"Xiao","year":"2008","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib63","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2230.2011.04197.x","article-title":"Efficacy of narrowband ultraviolet B twice weekly for hypopigmented mycosis fungoides in Asians","volume":"37","author":"Kanokrungsee","year":"2012","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib64","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1365-2133.2005.07085.x","article-title":"Photocarcinogenic risk of narrowband ultraviolet B (TL-01) phototherapy: early follow-up data","volume":"154","author":"Black","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib65","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2133.2005.06537.x","article-title":"The photocarcinogenic risk of narrowband UVB (TL-01) phototherapy: early follow-up data","volume":"152","author":"Man","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib66","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/00015550410026948","article-title":"No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study","volume":"84","author":"Weischer","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2013.08.033_bib67","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1600-0781.2007.00315.x","article-title":"Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides","volume":"23","author":"Lokitz","year":"2007","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2013.08.033_bib68","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1396-0296.2003.01647.x","article-title":"Mycosis fungoides: radiation therapy","volume":"16","author":"Hoppe","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2013.08.033_bib69","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.semradonc.2007.02.001","article-title":"Cutaneous lymphomas","volume":"17","author":"Smith","year":"2007","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib70","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000429580","article-title":"Total skin electron beam therapy in the management of mycosis fungoides","volume":"25","author":"Hoppe","year":"1991","journal-title":"Front Radiat Ther Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib71","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jaad.2007.12.016","article-title":"Total skin electron beam therapy may be associated with improvement of peripheral blood disease in S\u00e9zary syndrome","volume":"58","author":"Introcaso","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib72","first-page":"1985","article-title":"Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the S\u00e9zary syndrome)","volume":"85","author":"Jones","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2013.08.033_bib73","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0360-3016(98)00517-3","article-title":"Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides","volume":"43","author":"Chinn","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jaad.2013.08.033_bib74","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0889-8588(18)30058-3","article-title":"Electron beam treatment for cutaneous T-cell lymphoma","volume":"9","author":"Jones","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jaad.2013.08.033_bib75","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archdermatol.2011.98","article-title":"The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides","volume":"147","author":"Navi","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib76","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0360-3016(97)00127-2","article-title":"Total skin electron beam therapy followed by adjuvant psoralen\/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides)","volume":"38","author":"Quiros","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jaad.2013.08.033_bib77","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2133.2006.07559.x","article-title":"Does adjuvant alpha-interferon improve outcome when combined with total skin irradiation for mycosis fungoides?","volume":"156","author":"Roberge","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib78","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1067\/mjd.2000.105510","article-title":"Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides","volume":"43","author":"Wilson","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib79","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/0360-3016(95)00073-8","article-title":"Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy","volume":"32","author":"Wilson","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jaad.2013.08.033_bib80","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0190-9622(92)70142-3","article-title":"Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome)","volume":"26","author":"Jones","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib81","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1016\/j.ijrobp.2011.01.023","article-title":"Revisiting low-dose total skin electron beam therapy in mycosis fungoides","volume":"81","author":"Harrison","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jaad.2013.08.033_bib82","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/archderm.1978.01640130027008","article-title":"Radiation dermatitis following electron beam therapy. An evaluation of patients ten years after total skin irradiation for mycosis fungoides","volume":"114","author":"Price","year":"1978","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib83","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0360-3016(97)00553-1","article-title":"Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (mycosis fungoides)","volume":"40","author":"Wilson","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jaad.2013.08.033_bib84","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/0360-3016(83)90321-8","article-title":"Palliative radiation treatment of cutaneous mycosis fungoides\u2014a dose response","volume":"9","author":"Cotter","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jaad.2013.08.033_bib85","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","article-title":"Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas","volume":"74","author":"Neelis","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jaad.2013.08.033_bib86","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ijrobp.2012.05.034","article-title":"Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma","volume":"85","author":"Thomas","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jaad.2013.08.033_bib87","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1200\/JCO.2007.11.6202","article-title":"Inhibition of histone deacetylation: a strategy for tumor radiosensitization","volume":"25","author":"Camphausen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib88","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1365-2133.2012.10905.x","article-title":"Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions","volume":"167","author":"Akilov","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib89","article-title":"Phase II trial of all-trans retinoic acid (ATRA) in the treatment of relapsed\/refractory mycosis fungoides\/S\u00e9zary syndrome (MF\/SS)","volume":"94","author":"Siegel","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.08.033_bib90","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1200\/JCO.1994.12.6.1185","article-title":"Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study","volume":"12","author":"Cheng","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib91","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1002\/1097-0142(19910515)67:10<2490::AID-CNCR2820671017>3.0.CO;2-Q","article-title":"13-cis-retinoic acid induces cellular-differentiation and durable remission in\u00a0refractory cutaneous Ki-1 lymphoma","volume":"67","author":"Chow","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2013.08.033_bib92","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archderm.1987.01660260071016","article-title":"Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides)","volume":"123","author":"Kessler","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib93","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2340\/0001555567232236","article-title":"Oral retinoids in mycosis fungoides and S\u00e9zary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group","volume":"67","author":"Molin","year":"1987","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2013.08.033_bib94","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2133.1983.tb03991.x","article-title":"Treatment of cutaneous lymphoma with etretinate","volume":"109","author":"Claudy","year":"1983","journal-title":"Brit J Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib95","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(83)92136-0","article-title":"Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid","volume":"1","author":"Kessler","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2013.08.033_bib96","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ajh.20952","article-title":"Bexarotene blunts malignant T-cell chemotaxis in S\u00e9zary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine","volume":"82","author":"Richardson","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaad.2013.08.033_bib97","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib98","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib99","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2009.09037.x","article-title":"Bexarotene therapy for mycosis fungoides and S\u00e9zary syndrome","volume":"160","author":"Abbott","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2003.11.058","article-title":"Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous T-cell lymphoma","volume":"51","author":"Querfeld","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib101","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T-cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib102","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaad.2003.05.010","article-title":"Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series","volume":"51","author":"Singh","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib103","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1365-2133.2007.07901.x","article-title":"Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and S\u00e9zary syndrome","volume":"156","author":"Tsirigotis","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib104","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/cncr.22596","article-title":"Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma","volume":"109","author":"Straus","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2013.08.033_bib105","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1365-2133.2012.11156.x","article-title":"Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056)","volume":"167","author":"Whittaker","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib106","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/09546630903103980","article-title":"Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB","volume":"21","author":"D'Acunto","year":"2010","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2013.08.033_bib107","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0889-8588(18)30060-1","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Olsen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jaad.2013.08.033_bib108","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1396-0296.2003.01643.x","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"16","author":"Olsen","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2013.08.033_bib109","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0190-9622(89)70127-4","article-title":"Comparative study of systemic interferon alfa-nl and isotretinoin in the treatment of resistant condylomata acuminata","volume":"20","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib110","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(89)70049-9","article-title":"Interferon alfa-2a in the treatment of cutaneous T cell lymphoma","volume":"20","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib111","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2133.1999.02704.x","article-title":"Long-term follow-up in 51 patients with mycosis fungoides and S\u00e9zary syndrome treated by interferon-alfa","volume":"140","author":"Jumbou","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib112","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/978-3-642-78771-3_30","article-title":"Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy","volume":"139","author":"Stadler","year":"1995","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.jaad.2013.08.033_bib113","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0140-6736(05)66242-3","article-title":"Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma","volume":"350","author":"Dippel","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2013.08.033_bib114","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1001\/archderm.139.7.909","article-title":"Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy","volume":"139","author":"Ferenczi","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib115","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0190-9622(99)70351-8","article-title":"Durable loss of a malignant T-cell clone in a stage IV cutaneous T-cell lymphoma patient treated with high-dose interferon and photopheresis","volume":"41","author":"Haley","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib116","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/archderm.1991.01680090099012","article-title":"Combined therapy for S\u00e9zary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Clinical, molecular, and immunologic observations","volume":"127","author":"Rook","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib117","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00000421-199406000-00016","article-title":"Extracorporeal photopheresis and recombinant interferon alfa 2b in S\u00e9zary syndrome. Use of dual marker labeling to monitor therapeutic response","volume":"17","author":"Vonderheid","year":"1994","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib118","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jnci\/82.3.208","article-title":"Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma","volume":"82","author":"Kaplan","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2013.08.033_bib119","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaad.2008.05.038","article-title":"Extracorporeal photopheresis for the treatment of S\u00e9zary syndrome using a novel treatment protocol","volume":"59","author":"Arulogun","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib120","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/blood-2009-11-256040","article-title":"Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy","volume":"116","author":"Berger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.08.033_bib121","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2013.08.033_bib122","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1600-0781.2012.00689.x","article-title":"Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis","volume":"28","author":"Knobler","year":"2012","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2013.08.033_bib123","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0190-9622(96)90683-0","article-title":"Photopheresis therapy for cutaneous T-cell lymphoma","volume":"35","author":"Duvic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib124","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.2741\/3566","article-title":"Extracorporeal photoimmunotherapy-photopheresis","volume":"14","author":"Dani","year":"2009","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.jaad.2013.08.033_bib125","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/archderm.135.5.600","article-title":"S\u00e9zary syndrome, cutaneous T-cell lymphoma, and extracorporeal photopheresis","volume":"135","author":"Edelson","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib126","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/12034754030070S402","article-title":"Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2003","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2013.08.033_bib127","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1600-0781.2010.00514.x","article-title":"Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and S\u00e9zary syndrome","volume":"26","author":"McGirt","year":"2010","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2013.08.033_bib128","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/archderm.138.8.1054","article-title":"Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution","volume":"138","author":"Suchin","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib129","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1749-6632.2001.tb03726.x","article-title":"Treatment of cutaneous T cell lymphoma stage II with interferon-alpha-2a and extracorporeal photochemotherapy: a prospective controlled trial","volume":"941","author":"Wollina","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaad.2013.08.033_bib130","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1067\/mjd.2000.104852","article-title":"Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution","volume":"43","author":"Bisaccia","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib131","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0190-9622(96)90119-X","article-title":"Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution","volume":"35","author":"Gottlieb","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib132","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clml.2011.03.003","article-title":"Multicenter photopheresis intervention trial in early-stage mycosis fungoides","volume":"11","author":"Talpur","year":"2011","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"10.1016\/j.jaad.2013.08.033_bib133","doi-asserted-by":"crossref","first-page":"117ra7","DOI":"10.1126\/scitranslmed.3003008","article-title":"Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients","volume":"4","author":"Clark","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaad.2013.08.033_bib134","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3109\/10428191003777963","article-title":"Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models","volume":"51","author":"Siders","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2013.08.033_bib135","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","volume":"128","author":"Hu","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jaad.2013.08.033_bib136","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1432-2277.2006.00382.x","article-title":"Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood","volume":"19","author":"Lowenstein","year":"2006","journal-title":"Transpl Int"},{"key":"10.1016\/j.jaad.2013.08.033_bib137","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.leukres.2007.11.009","article-title":"Subcutaneous alemtuzumab for S\u00e9zary syndrome in the very elderly","volume":"32","author":"Alinari","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaad.2013.08.033_bib138","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1365-2133.2001.04014.x","article-title":"The relevance of the CD4+ CD26\u2013 subset in the identification of circulating S\u00e9zary cells","volume":"144","author":"Bernengo","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib139","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1046\/j.0902-4441.2004.00169.x","article-title":"Successful treatment of chemotherapy-refractory S\u00e9zary syndrome with alemtuzumab (Campath-1H)","volume":"72","author":"Gautschi","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaad.2013.08.033_bib140","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and S\u00e9zary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaad.2013.08.033_bib141","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3109\/10428190903216770","article-title":"Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center","volume":"50","author":"Querfeld","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2013.08.033_bib142","first-page":"702","article-title":"Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma","volume":"90","author":"Zinzani","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.jaad.2013.08.033_bib143","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/S\u00e9zary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.08.033_bib144","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of S\u00e9zary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.jaad.2013.08.033_bib145","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/j.1476-5381.2010.01188.x","article-title":"The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells","volume":"162","author":"Tiffon","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaad.2013.08.033_bib146","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3109\/10428194.2012.656625","article-title":"Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in\u00a0vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor\/retinoid X receptor activation by histone deacetylase inhibition","volume":"53","author":"Dummer","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2013.08.033_bib147","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib148","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3816\/CLM.2009.n.082","article-title":"Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma","volume":"9","author":"Duvic","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.jaad.2013.08.033_bib149","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib150","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib151","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/10428194.2012.711829","article-title":"Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin","volume":"54","author":"Kim","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2013.08.033_bib152","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ajh.23112","article-title":"The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients","volume":"87","author":"Kelly-Sell","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaad.2013.08.033_bib153","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s00105-006-1189-5","article-title":"Cutaneous lymphomas: classification and stage-adjusted therapy [in German]","volume":"57","author":"Stadler","year":"2006","journal-title":"Hautarzt"},{"key":"10.1016\/j.jaad.2013.08.033_bib154","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.jid.5700122","article-title":"CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma","volume":"126","author":"Talpur","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib155","doi-asserted-by":"crossref","first-page":"11885","DOI":"10.1016\/S0021-9258(19)38482-0","article-title":"Structure\/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells","volume":"265","author":"Williams","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaad.2013.08.033_bib156","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0190-9622(98)70403-7","article-title":"Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides","volume":"39","author":"Saleh","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib157","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib158","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib159","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.clml.2013.02.020","article-title":"Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies","volume":"13","author":"Duvic","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jaad.2013.08.033_bib160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/10428194.2012.706286","article-title":"Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and S\u00e9zary syndrome","volume":"54","author":"Prince","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2013.08.033_bib161","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00280-009-0954-4","article-title":"Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in\u00a0vitro and in\u00a0vivo models of human cancers","volume":"64","author":"Izbicka","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jaad.2013.08.033_bib162","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/1042819031000077124","article-title":"Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression","volume":"44","author":"Wang","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2013.08.033_bib163","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1517\/17425255.2011.595404","article-title":"Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma","volume":"7","author":"Foss","year":"2011","journal-title":"Exp Opin Drug Metabol Toxicol"},{"key":"10.1016\/j.jaad.2013.08.033_bib164","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0190-9622(96)80062-4","article-title":"Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients","volume":"34","author":"Zackheim","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib165","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0190-9622(03)01591-3","article-title":"Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients","volume":"49","author":"Zackheim","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib166","first-page":"1009","article-title":"Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorum factor","volume":"62","author":"McDonald","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.jaad.2013.08.033_bib167","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.08.033_bib168","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2012.01.010","article-title":"Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study","volume":"12","author":"Foss","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jaad.2013.08.033_bib169","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jaad.2013.08.033_bib170","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2013.08.033_bib171","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012","volume":"30","author":"Dummer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib172","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2013.08.033_bib173","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.bmt.1705968","article-title":"Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma","volume":"41","author":"Duarte","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaad.2013.08.033_bib174","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0889-8588(03)00114-X","article-title":"High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma","volume":"17","author":"Oyama","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jaad.2013.08.033_bib175","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","article-title":"Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and S\u00e9zary syndrome","volume":"28","author":"Duvic","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib176","first-page":"133","article-title":"Autologous bone marrow transplantation for advanced stage mycosis fungoides","volume":"7","author":"Bigler","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaad.2013.08.033_bib177","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.bmt.1704411","article-title":"High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma","volume":"33","author":"Ingen-Housz-Oro","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaad.2013.08.033_bib178","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1046\/j.1365-2141.2001.02919.x","article-title":"T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement","volume":"114","author":"Olavarria","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2013.08.033_bib179","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1749-6632.2001.tb03718.x","article-title":"Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival","volume":"941","author":"Russell-Jones","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaad.2013.08.033_bib180","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2230.1995.tb01291.x","article-title":"Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplantation","volume":"20","author":"Sterling","year":"1995","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib181","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.08.033_bib182","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2003-02-0342","article-title":"Graft-versus-leukemia reactions in allogeneic chimeras","volume":"103","author":"Kolb","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.08.033_bib183","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","article-title":"Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Duarte","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib184","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2009.04.017","article-title":"A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and S\u00e9zary syndrome","volume":"15","author":"Wu","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaad.2013.08.033_bib185","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymthe.2005.09.011","article-title":"Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders","volume":"13","author":"Baron","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaad.2013.08.033_bib186","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.bmt.1704641","article-title":"Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation","volume":"34","author":"Herbert","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaad.2013.08.033_bib187","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000151510","article-title":"Durable remission of S\u00e9zary syndrome after unrelated bone marrow transplantation by reduced-intensity conditioning","volume":"120","author":"Kahata","year":"2008","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jaad.2013.08.033_bib188","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaad.2013.08.033_bib189","doi-asserted-by":"crossref","unstructured":"Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, Kuzel TM. Phase II multicenter trial of lenalidomide: clinical and immunomodulatory effects in patients with CTCL. 53rd ASH (American Society of Hematology) Annual Meeting and Exposition San Diego, California, December 12, 2011.","DOI":"10.1182\/blood.V118.21.1638.1638"},{"key":"10.1016\/j.jaad.2013.08.033_bib190","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd2059","article-title":"Therapeutic potential of Toll-like receptor 9 activation","volume":"5","author":"Krieg","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaad.2013.08.033_bib191","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jaad.2009.12.052","article-title":"Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma","volume":"63","author":"Kim","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib192","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaad.2006.06.038","article-title":"A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides","volume":"55","author":"Duvic","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib193","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaad.2006.08.067","article-title":"Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and S\u00e9zary syndrome","volume":"56","author":"Querfeld","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib194","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0889-8588(03)00109-6","article-title":"Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2","volume":"17","author":"Rook","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jaad.2013.08.033_bib195","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1749-6632.2001.tb03721.x","article-title":"The role for interleukin-12 therapy of cutaneous T cell lymphoma","volume":"941","author":"Rook","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaad.2013.08.033_bib196","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2006-12-062877","article-title":"Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma","volume":"109","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.08.033_bib197","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/1078-0432.CCR-07-1324","article-title":"Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive\/refractory mycosis fungoides and S\u00e9zary syndrome","volume":"13","author":"Yano","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2013.08.033_bib198","doi-asserted-by":"crossref","first-page":"e44455","DOI":"10.1371\/journal.pone.0044455","article-title":"Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma","volume":"7","author":"Han","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.jaad.2013.08.033_bib199","doi-asserted-by":"crossref","first-page":"5996","DOI":"10.1158\/0008-5472.CAN-08-4619","article-title":"Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells","volume":"69","author":"Olkhanud","year":"2009","journal-title":"Cancer research"},{"key":"10.1016\/j.jaad.2013.08.033_bib200","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2013.08.033_bib201","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1158\/1535-7163.MCT-12-0278","article-title":"Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells","volume":"11","author":"Chang","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jaad.2013.08.033_bib202","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2005-06-2536","article-title":"Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis","volume":"107","author":"Sors","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.08.033_bib203","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib204","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1158\/1078-0432.CCR-12-0181","article-title":"A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia","volume":"18","author":"Ghobrial","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2013.08.033_bib205","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/annonc\/mdm463","article-title":"A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma","volume":"19","author":"Morschhauser","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib206","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.2006.09.3146","article-title":"Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"25","author":"Robertson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.08.033_bib207","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/sj.jid.5700322","article-title":"The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway","volume":"126","author":"Querfeld","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.08.033_bib208","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3109\/10428194.2011.572265","article-title":"Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma","volume":"52","author":"Querfeld","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2013.08.033_bib209","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3324\/haematol.2009.013870","article-title":"Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma","volume":"95","author":"Wozniak","year":"2010","journal-title":"Haematologica"},{"issue":"3 Suppl","key":"10.1016\/j.jaad.2013.08.033_bib210","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.sder.2012.07.004","article-title":"Treatment strategies for atopic dermatitis: optimizing the available therapeutic options","volume":"31","author":"Paller","year":"2012","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2013.08.033_bib211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0011-5029(57)80005-4","article-title":"Thermal burns","volume":"9","author":"Levenson","year":"1957","journal-title":"Dis Mon"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213009079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213009079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:29:17Z","timestamp":1759271357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962213009079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":211,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0190962213009079"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2013.08.033","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome)","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2013.08.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}